Aviso: Este sitio agrega datos públicos oficiales de la FDA, ClinicalTrials.gov, PubMed y SEC EDGAR solo como referencia general. No constituye asesoramiento médico, diagnóstico, recomendaciones de tratamiento ni asesoramiento de inversión.

Ensayo clínico

Study of the Disease Process of Lymphangioleiomyomatosis

NCT: NCT00001465 · RECRUITING

ID NCTNCT00001465
EstadoRECRUITING
Fecha de inicio1995-12-18
SponsorNational Heart, Lung, and Blood Institute (NHLBI) (NIH)
First posted
Last updated

Resumen breve

Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy. Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals.

Fuente oficial

Ver en ClinicalTrials.gov →

Datos obtenidos de la API de ClinicalTrials.gov. Para conocer el estado más reciente, consulte el registro oficial.

↑